Dr. Reddy's Labs

    DRREDDY
    Pharma
    ₹1,229.50
    Price as of 25 Oct 2026, 10:28 pm IST

    Market cap ₹1.02 L Cr

    P/E
    36.60
    Day range
    ₹1,215.60 – ₹1,250.60
    52-week range
    ₹1,101.00 – ₹1,414.90
    Volume
    15.50 L
    Open
    ₹1,236.20
    Prev close
    ₹1,239.00

    Latest results · Q2 FY27(consolidated)Revenue ₹8,698 Cr-1.5%Profit ₹913 Cr-31.7%Margin 10.5%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Weak financial health score

      Piotroski 2 of 8 tests passed · 30 Jun 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    DRREDDY in NSE indices and F&O

    F&O margin for one lot of DRREDDY (625 shares)

    Research profile

    Composite 62 / 100

    Factor percentiles

    Value55
    Quality34
    Momentum66
    Low volatility95

    Derived metrics

    Earn. yield
    2.7%
    Graham no.
    ₹625.51
    vs Graham
    -49.1%
    ROE ÷ P/B
    4.3%
    12-1 mom.
    -2.1%
    Return / vol
    -0.03
    Magic Formula
    #443
    Piotroski
    2/8
    FCF yield
    1.8%

    Appears in 6 scans

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 67 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.19 L Cr34.685.0214.8%21.0%29.0%0.06+10.5%
    Divi's LaboratoriesDIVISLAB₹2.38 L Cr81.2114.5216.2%22.0%41.0%0.00+27.8%
    Torrent PharmaTORNTPHARM₹1.72 L Cr76.439.3726.8%15.0%33.0%0.77+50.8%
    Zydus LifesciencesZYDUSLIFE₹1.13 L Cr25.174.2020.1%21.0%24.0%0.46+22.0%
    Apollo HospitalsAPOLLOHOSP₹1.11 L Cr53.1911.5422.6%17.0%16.0%0.90+20.6%
    CiplaCIPLA₹1.08 L Cr32.093.1211.8%15.0%17.0%0.02+2.3%
    Laurus LabsLAURUSLABS₹1.06 L Cr97.3820.0618.2%18.0%32.0%0.48+29.0%
    Dr. Reddy's LabsDRREDDY₹1.02 L Cr36.602.7311.6%13.0%11.0%0.20-5.5%
    Sector median₹23,579 Cr41.615.6015.1%17.0%25.0%0.16+20.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 3d ago

    Headlines about Dr. Reddy's Labs from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.

    Key metrics

    P/E (TTM)
    36.6
    Price / Book
    2.64
    ROE (FY26)
    11.6%
    ROCE (latest year)
    13%
    Dividend yield
    0.65%

    Moving averages (NSE)

    20-day
    ₹1,219.9
    Price above
    50-day
    ₹1,192.44
    Price above
    200-day
    ₹1,243.77
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +11.0%
    Profit 3Y CAGR
    -2.7%
    Revenue YoY (Sep 2026)
    -1.5%
    Profit YoY (Sep 2026)
    -31.7%
    Operating margin
    20.0%
    Net margin
    10.5%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • DII
    • Promoter
    • Public
    • FII
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-10K Cr-5K Cr0 Cr5K Cr10K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr10K Cr20K Cr30K Cr40K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the split of 28 Oct 2024: earlier bars are per pre-split share.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹10₹20₹30₹40

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales7,2377,1147,6968,0388,3818,5288,5728,8288,7537,5468,1008,698
    Expenses5,2145,2835,5665,9626,1086,5306,3986,8186,8667,1647,2406,975
    Operating Profit2,0231,8312,1302,0762,2731,9982,1742,0101,8883828601,723
    OPM %28%26%28%26%27%23%25%23%22%5%11%20%
    Other Income219201193314154528290330271480356156
    Interest395960768266839194106126125
    Depreciation374368381397471455476505521557537527
    Profit before tax1,8291,6051,8831,9171,8742,0051,9051,7451,5432005531,228
    Tax %24%18%26%30%25%21%26%23%23%-11%21%26%
    Net Profit1,3811,3101,3921,3421,4041,5871,4101,3371,190221436913
    EPS in Rs₹16.56₹15.70₹16.69₹15.05₹16.94₹19.09₹16.99₹16.14₹14.50₹2.65₹5.32₹11.08

    From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days110

    +15 days since Mar 2021

    Inventory Days228

    -45 days since Mar 2021

    Days Payable91

    -18 days since Mar 2021

    Cash Conversion Cycle247

    -12 days since Mar 2021

    Working Capital Days68

    +11 days since Mar 2021

    Strengths, risks & growth

    Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

    Strengths

    • Company's working capital requirements have reduced from 85.1 days to 67.8 days

    Risks

    • Dividend payout has been low at 13.2% of profits over last 3 years

    Compounded Sales Growth

    10 Years
    +8%
    5 Years
    +12%
    3 Years
    +11%
    TTM
    -4%

    Compounded Profit Growth

    10 Years
    +7%
    5 Years
    +15%
    3 Years
    -4%
    TTM
    -51%

    Stock Price CAGR

    10 Years
    +6%
    5 Years
    +6%
    3 Years
    +4%
    1 Year
    -4%

    Return on Equity

    10 Years
    +15%
    5 Years
    +16%
    3 Years
    +16%
    Last Year
    +11%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter26.64%26.63%26.63%26.63%0.00 pp
    FII22.34%21.14%20.67%20.30%-0.37 pp
    DII30.44%30.72%31.75%31.87%+0.12 pp
    Public20.33%21.27%20.76%20.99%+0.23 pp
    Others0.25%0.24%0.20%0.19%-0.01 pp

    Filed with NSE for Sept 2026: promoters 26.63%, public 73.17% · XBRL filing

    Analysts & fund holdings

    62%
    62% recommend buy
    29 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E36.6 vs 44.2
    Sector P/B5.54
    Beta0.39

    Who holds the shares, quarter by quarter

    Mutual funds 14.16% (+0.98 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters26.7%
    • Foreign institutions20.3%
    • Mutual funds14.2%
    • Insurance14.6%
    • Other domestic institutions3.1%
    • Retail7.5%
    • Others13.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Parag Parikh Flexi Cap Fund1.74%1.23%-0.04 pp
    ICICI Pru Value Fund1.15%2.06%-0.07 pp
    ICICI Pru India Opp Fund0.99%2.65%+1.90 pp
    ICICI Pru Large Cap Fund0.76%1.02%+0.15 pp
    ICICI Pru Healthcare Fund0.66%9.73%+1.50 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Avg
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Risk & trend

    From 275 daily sessions to 23 Oct 2026.

    Computed

    Risk

    Volatility (1Y)
    23.2%
    Downside volatility
    21.5%
    Worst 5% of days
    2.0%
    Average of that tail
    3.1%
    Max drawdown (1Y)
    17.5%
    Below its peak
    10.6%

    Against the market

    Beta vs Nifty 50
    0.49
    Correlation
    0.28
    Relative strength (3M)
    +10.7%
    ATR (14)
    2.2%

    Return

    Return 1M
    +1.5%
    Return 3M
    +5.4%
    Return 6M
    +1.0%
    Return 1Y
    -0.6%
    vs 200-day average
    -1.1%

    Momentum

    RSI (14)
    55.2
    MACD histogram
    1.25
    Stochastic %K
    73.5
    ADX (14)
    20.9
    +DI / −DI
    22.4 / 18.0
    Money flow index
    49.9

    Participation

    Delivery (20d avg)
    54.8%
    vs its 60-day baseline
    -0.9 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    -0.0%
    52-week position
    39 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Jun 2026.

    Computed

    Piotroski F-Score

    2 of 8 tested

    • Return on assets positive — passed
    • Operating cash flow positive — failed
    • Return on assets improving — failed
    • Cash flow exceeds profit — failed
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    ₹1,833 Cr
    FCF yield
    1.8%
    Cash conversion
    1.37
    Accruals ratio
    -0.026
    Net debt
    ₹6,075 Cr
    Net debt / equity
    0.16
    EV / sales
    3.28
    Capex intensity
    11.4%
    Revenue CAGR
    -5.5%
    Profit CAGR
    -69.1%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹1.6 Cr
    3 buys · ₹1.6 Cr
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Tricia Wetzel
    Designated Person · ESOP
    		Buy4,275₹54.2 L23 Jun 2026
    Patrick Aghanian
    ESOP
    		Buy3,675₹47.8 L30 Mar 2026
    Tricia Wetzel
    ESOP
    		Buy4,275₹54.2 L12 Dec 2025
    Patrick Aghanian
    ESOP
    		Buy4,775₹62.9 L17 Sept 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹8.00

      Dividend - Rs 8 Per Share

      10 Jul 2026
      ex-date
    • dividend
      ₹8.00

      Dividend - Rs 8 Per Share

      10 Jul 2025
      ex-date
    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share

      28 Oct 2024
      ex-date
    • dividend
      ₹40.00

      Annual General Meeting/Dividend - Rs 40 Per Share

      16 Jul 2024
      ex-date
    • dividend
      ₹40.00

      Annual General Meeting/Dividend - Rs 40 Per Share

      11 Jul 2023
      ex-date
    • dividend
      ₹30.00

      Annual General Meeting/Dividend - Rs 30 Per Share

      11 Jul 2022
      ex-date
    • dividend
      ₹25.00

      Annual General Meeting/Dividend - Rs 25 Per Share

      9 Jul 2021
      ex-date
    • dividend
      ₹25.00

      Annual General Meeting/Dividend - Rs 25 Per Share

      13 Jul 2020
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/Dividend - Rs 20 Per Share

      15 Jul 2019
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/Dividend- Rs 20 Per Share

      16 Jul 2018
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/Dividend - Rs 20/- Per Share

      17 Jul 2017
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/ Dividend - Rs 20/- Per Share

      18 Jul 2016
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/Dividend Rs 20/- Per Share

      10 Jul 2015
      ex-date
    • dividend
      ₹18.00

      Annual General Meeting / Final Dividend - Rs 18/- Per Share

      11 Jul 2014
      ex-date
    • dividend
      ₹15.00

      Annual General Meeting And Dividend Rs.15/- Per Share

      12 Jul 2013
      ex-date
    • dividend
      ₹13.75

      Annual General Meeting And Dividend - Rs.13.75 Per Share

      28 Jun 2012
      ex-date
    • dividend
      ₹11.25

      Annual General Meeting And Dividend Rs.11.25 Per Share

      30 Jun 2011
      ex-date
    • bonus
      Not available — not reported in this filing

      Scheme Of Arrangement - Bonus Debentures 6:1

      17 Mar 2011
      ex-date
    • dividend
      ₹11.25

      Annual General Meeting And Final Dividend Rs.11.25 Per Share

      2 Jul 2010
      ex-date
    • other
      Not available — not reported in this filing

      Agm/Div-Rs.6.25 Per Share

      3 Jul 2009
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update
    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update
    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Intimation of Earnings call

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018

    Company Update
    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Insider Trading / SAST
    Closure of Trading Window

    Closure of Trading window

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending September 30, 2026.

    Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve Unaudited Standalone ....

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of analyst meet

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update
    Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company UpdatePrice-sensitive
    Clarification sought from Dr Reddys Laboratories Ltd

    The Exchange has sought clarification from Dr Reddys Laboratories Ltd on September 17, 2026, with reference to news appeared in https://pharma.economictimes.indiatimes.com/ dated September ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copies of newspaper publication

    Company Update
    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of Employee Stock options

    Filed with BSE (scrip 500124); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 24 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Dr. Reddy's Labs: common questions

    Answered from the figures on this page.

    Dr. Reddy's Labs last traded at ₹1,229.50 (NSE, as of 25 Oct 2026). The last session moved it down 0.77%.

    Dr. Reddy's Labs is valued at about ₹1.02 lakh crore (NSE, as of 25 Oct 2026).

    Dr. Reddy's Labs trades at a price-to-earnings ratio of 36.60 (NSE, as of 25 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Dr. Reddy's Labs has traded between ₹1,101.00 and ₹1,414.90 over the past 52 weeks, to 25 Oct 2026. It is currently 41% of the way up that range.

    Dr. Reddy's Labs (DRREDDY) is classified under Pharma on this site's screener.